Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

PCSK9: a key modulator of cardiovascular health.

Seidah NG, Awan Z, Chrétien M, Mbikay M.

Circ Res. 2014 Mar 14;114(6):1022-36. doi: 10.1161/CIRCRESAHA.114.301621. Review.

2.

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.

Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.

Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080. Review.

3.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.

Awan Z, Baass A, Genest J.

Clin Chem. 2014 Nov;60(11):1380-9. doi: 10.1373/clinchem.2014.225946. Epub 2014 Sep 23. Review.

4.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

5.

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Poirier S, Mayer G.

Drug Des Devel Ther. 2013 Oct 4;7:1135-48. doi: 10.2147/DDDT.S36984. eCollection 2013. Review.

6.
7.

PCSK9 inhibitors.

Gencer B, Lambert G, Mach F.

Swiss Med Wkly. 2015 Apr 9;145:w14094. doi: 10.4414/smw.2015.14094. eCollection 2015. Review.

8.

PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

Marais AD, Kim JB, Wasserman SM, Lambert G.

Pharmacol Ther. 2015 Jan;145:58-66. doi: 10.1016/j.pharmthera.2014.07.004. Epub 2014 Jul 18. Review.

PMID:
25046268
9.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.

10.

PCSK9: From discovery to therapeutic applications.

Farnier M.

Arch Cardiovasc Dis. 2014 Jan;107(1):58-66. doi: 10.1016/j.acvd.2013.10.007. Epub 2013 Dec 27. Review.

11.

PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.

Saavedra YG, Dufour R, Davignon J, Baass A.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2700-5. doi: 10.1161/ATVBAHA.114.304406. Epub 2014 Oct 2.

12.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.

Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.

Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):835-43. doi: 10.1016/j.numecd.2011.06.002. Epub 2011 Sep 23. Review.

PMID:
21943799
13.

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.

Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A.

Int J Biol Sci. 2012;8(3):310-27. doi: 10.7150/ijbs.3524. Epub 2012 Feb 9.

14.

An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.

Schiele F, Park J, Redemann N, Luippold G, Nar H.

J Mol Biol. 2014 Feb 20;426(4):843-52. doi: 10.1016/j.jmb.2013.11.011. Epub 2013 Nov 16.

PMID:
24252255
15.

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.

Lagace TA.

Curr Opin Lipidol. 2014 Oct;25(5):387-93. doi: 10.1097/MOL.0000000000000114. Review.

16.
17.

Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.

Lopez D.

Drug News Perspect. 2008 Jul-Aug;21(6):323-30. doi: 10.1358/dnp.2008.21.6.1246795. Review.

PMID:
18836590
18.

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.

Costet P, Krempf M, Cariou B.

Trends Biochem Sci. 2008 Sep;33(9):426-34. doi: 10.1016/j.tibs.2008.06.005. Epub 2008 Jul 30. Review.

PMID:
18672372
19.

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.

Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH.

J Biol Chem. 2007 Jun 22;282(25):18602-12. Epub 2007 Apr 23.

20.

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.

Maxwell KN, Breslow JL.

Curr Opin Lipidol. 2005 Apr;16(2):167-72. Review.

PMID:
15767856

Supplemental Content

Support Center